Investment opportunities
Open for Investment
Lipozyt Marker
Diagnostic Tests for the Personalized Treatment of Type 2 Diabetes
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreeOpen for Investment
Munevo
Smartglasses helping people with disabilities to achieve independent mobility
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreePrivate Placement
Alma Bio Therapeutics
Targeting the cause of Autoimmune Disease – restoring immune balance without suppressing the system itself
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreePrivate Placement
Mowoot
Solving intestinal transit disorders purely physical, non-drug, non-invasive
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreePrivate Placement
NanoVelos
Getting drugs to their targets with significant side effects reduction
New from the blog
-
Read full story
29.12.2020
The future of digital diabetes management: The ESYSTA Pen 2.0
On achieving the 3-million-euro financing threshold, Emperra plans to start the development of the ESYSTA Pen 2.0. But why? How will it differ from the current ESYSTA Pen? And why is this such an important factor for Emperra's international growth? Find out the answers to these questions and more in the following article.
-
Read full story
17.12.2020
What do the studies say? The benefit of the ESYSTA System is clinically proven.
It is possibly the most pertinent question regarding the ESYSTA System: Is it beneficial? Or in more technical terms: Does using ESYSTA have a medical benefit for diabetes patients and if so, what is that benefit? These questions are not only at the forefront for patients, doctors and health insurance providers, Emperra, as the developer of the ESYSTA System, also wanted a straight answer.
-
Read full story
10.12.2020
The advantages of Emperra’s ESYSTA System
A diabetes diary is the most important source of data for successful diabetes treatment. Diabetes patients are required to enter their values in these diaries daily, sometimes up to 6 times a day. Gaps, mistakes or errors can complicate treatment. Alarmingly, however, meticulously kept diabetes diaries are a rarity.
-
Read full story
03.12.2020
The benefits of digitalisation for the healthcare sector
Digitalisation is not an end in itself but instead is gaining more and more traction in all areas of life due to the sum of its benefits. This naturally also applies to the benefits for the healthcare sector: In this sector, digital technologies and products such as, e.g. Emperra's ESYSTA system have the potential to overcome the major challenges of the upcoming years and decades, including demographic change, the consistent increase of chronic diseases and insufficient access to healthcare in economically underdeveloped, rural areas.
-
Read full story
27.11.2020
Why the German Digital Healthcare Act (DVG) is triggering such major investments
Digitalisation has the potential to genuinely improve the provision of healthcare in Germany. However, until recently, the integration of digital solutions was possible to only a very limited extent due to the general parameters of the German healthcare system. The German Digital Healthcare Act (Digitale-Versorgung-Gesetz, DVG) has now created conditions that do justice to the dynamism of digital transformation and the speed of its processes.
-
Read full story
19.11.2020
How the DVG is improving the scalability of Emperra’s digital services
The German Digital Healthcare Act is a major milestone on the path to the digitalisation of the German healthcare system. This development is fully in line with Emperras strategic focus.
-
Read full story
12.11.2020
Why experts are warning of a diabetes epidemic
Diabetes mellitus, and in particular type 2 diabetes, is becoming an affliction of global proportion. In 2006, the International Diabetes Federation (IDF) already referred to the issue as "THE epidemic of the 21st century". Unfortunately, this prediction has turned out to be virtually on point.
-
Read full story
10.07.2020
Investors in the Time of the Pandemic Meet Virtually at the Sachsforum
This week, the digital Novel Coronavirus Investment Forum (NCIF) offered a forward-looking analysis of the revolution in healthcare
-
Read full story
10.07.2020
Proteona and Aescuvest Cover 546 Kilometres in the Run Against Cancer
Since 2012, the National Center for Tumor Diseases (NCT) Heidelberg has been organizing a charity run against cancer. This year, Proteona teamed up with Aescuvest for the good cause.
-
Read full story
04.06.2020
How Surge-On Medical Defines the Future of Surgery
Defining the future of robotic surgery training and MIS instruments: Surge-on Medical started shaping their own VR trainer to deliver more value to the users.